Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention
2021-004271-14Phase 3Active
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin in aortic stenosis (AS), aortic insufficiency (AI) and heart failure (HF), sponsored by Aarhus University Hospital. Primary endpoint: Composite change in myocardial and renal function at 12 months. Started Oct 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
aortic stenosis (AS)aortic insufficiency (AI)heart failure (HF)
Beyond the preview
Go deeper on 2021-004271-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004271-14.